|
[1]BOSETTI C,TURATI F,La VECCHIA C.Hepatocellular carcinoma epidemiology[J].Best Pract Res Clin Gastroenterol,2014,28(5):753-770.
|
|
[2]SHEN Q,FAN J,YANG XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a largescale,multicentre study[J].Lancet Oncol,2012,13(8):817-826.
|
|
[3]FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):e359-e386.
|
|
[4]LI J,HUANG L,LIU CF,et al.Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma:a case-control study[J].World J Gastroenterol,2014,20(27):9121-9127.
|
|
[5]LI M,ZHOU W,YUAN R,et al.ROCK2 promotes HCC proliferation by CEBPD inhibition through phospho-GSK3beta/beta-catenin signaling[J].FEBS Lett,2015,589(9):1018-1025.
|
|
[6]SARASWAT VA,PANDEY G,SHETTY S.Treatment algorithms for managing hepatocellular carcinoma[J].J Clin Exp Hepatol,2014,4(Suppl 3):s80-s89.
|
|
[7]QUETGLAS IM,MOEINI A,PINYOL R,et al.Integration of genomic information in the clinical management of HCC[J].Best Pract Res Clin Gastroenterol,2014,28(5):831-842.
|
|
[8]BIRCHMEIER C,BIRCHMEIER W,GHERARDI E,et al.Met,metastasis,motility and more[J].Nat Rev Mol Cell Biol,2003,4(12):915-925.
|
|
[9]GIORDANO S,COLUMBANO A.Met as a therapeutic target in HCC:facts and hopes[J].J Hepatol,2014,60(2):442-452.
|
|
[10]COOPER CS,PARK M,BLAIR DG,et al.Molecular cloning of a new transforming gene from a chemically transformed human cell line[J].Nature,1984,311(5981):29-33.
|
|
[11]WU JG,YU JW,WU HB,et al.Expressions and clinical significances of c-MET,p-MET and E2f-1 in human gastric carcinoma[J].BMC Res Notes,2014,7:6.
|
|
[12]GAO W,BING X,LI M,et al.Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma[J].Med Oncol,2013,30(2):546.
|
|
[13]MA PC,MAULIK G,CHRISTENSEN J,et al.C-Met:structure,functions and potential for therapeutic inhibition[J].Cancer Metastasis Rev,2003,22(4):309-325.
|
|
[14]LEE SJ,LEE J,SOHN I,et al.A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma[J].Anticancer Res,2013,33(11):5179-5186.
|
|
[15]GOYAL L,MUZUMDAR MD,ZHU AX.Targeting the HGF/c-MET pathway in hepatocellular carcinoma[J].Clin Cancer Res,2013,19(9):2310-2318.
|
|
[16]UEKI T,FUJIMOTO J,SUZUKI T,et al.Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma[J].Hepatology,1997,25(4):862-866.
|
|
[17]ZHANG SZ,PAN FY,XU JF,et al.Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo[J].Mol Cancer Ther,2005,4(10):1577-1584.
|
|
[18]TIRAN Z,OREN A,HERMESH C,et al.A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway[J].Clin Cancer Res,2008,14(14):4612-4621.
|
|
[19]DANILKOVITCH-MIAGKOVA A,ZBAR B.Dysregulation of Met receptor tyrosine kinase activity in invasive tumors[J].J Clin Invest,2002,109(7):863-867.
|
|
[20]MENARD L,PARKER PJ,KERMORGANT S.Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways[J].Nat Commun,2014,5:3907.
|
|
[21]XIE B,XING R,CHEN P,et al.Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference[J].J Surg Res,2010,162(2):231-238.
|
|
[22]ABOUNADER R,LAL B,LUDDY C,et al.In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis[J].FASEB J,2002,16(1):108-110.
|
|
[23]CHU JS,GE FJ,ZHANG B,et al.Expression and prognostic value of VEGFR-2,PDGFR-beta,and c-Met in advanced hepatocellular carcinoma[J].J Exp Clin Cancer Res,2013,32:16.
|
|
[24]WANG ZL,LIANG P,DONG BW,et al.Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation:a retrospective study[J].J Gastrointest Surg,2008,12(2):327-337.
|
|
[25]LEUNG KK,HAUSE RJ,BARKINGE JL,et al.Enhanced prediction of Src homology 2(SH2)domain binding potentials using a fluorescence polarization-derived c-Met,c-Kit,Erb B,and androgen receptor interactome[J].Mol Cell Proteomics,2014,13(7):1705-1723.
|
|
[26]WANG W,XU S,YIN M,et al.Essential roles of Gab1 tyrosine phosphorylation in growth factor-mediated signaling and angiogenesis[J].Int J Cardiol,2015,181:180-184.
|
|
[27]KITADE M,FACTOR VM,ANDERSEN JB,et al.Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling[J].Genes Dev,2013,27(15):1706-1717.
|
|
[28]ELLERKAMP V,LIEBER J,NAGEL C,et al.Pharmacological inhibition of beta-catenin in hepatoblastoma cells[J].Pediatr Surg Int,2013,29(2):141-149.
|
|
[29]GAO J,INAGAKI Y,SONG P,et al.Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma[J].Pharmacol Res,2012,65(1):23-30.
|
|
[30]SHAH MA,WAINBERG ZA,CATENACCI DV,et al.Phase II study evaluating 2 dosing schedules of oral foretinib(GSK1363089),c MET/VEGFR2 inhibitor,in patients with metastatic gastric cancer[J].PLo S One,2013,8(3):e54014.
|
|
[31]AOYAMA A,KATAYAMA R,OH-HARA T,et al.Tivantinib(ARQ 197)exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance[J].Mol Cancer Ther,2014,13(12):2978-2990.
|
|
[32]INAGAKI Y,QI F,GAO J,et al.Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth[J].Biosci Trends,2011,5(2):52-56.
|
|
[33]HUYNH H,ONG R,SOO KC.Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma[J].Angiogenesis,2012,15(1):59-70.
|
|
[34]CHEN X,DING G,GAO Q,et al.A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma[J].PLo S One,2013,8(5):e63093.
|
DownLoad: